Market Closed -
Other stock markets
|
Pre-market 08:30:59 am | |||
146 USD | -1.24% | 146.5 | +0.37% |
11:20am | Citigroup Adjusts Price Target on Johnson & Johnson to $180 From $185, Keeps Buy Rating | MT |
Jun. 05 | J&J: applies to FDA for expanded indication for Prezcobix | CF |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- With an enterprise value anticipated at 3.9 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.87% | 351B | C+ | ||
+42.69% | 749B | C+ | ||
+38.81% | 605B | B | ||
+18.74% | 328B | B- | ||
+6.76% | 292B | C+ | ||
+18.89% | 248B | B+ | ||
-2.29% | 214B | A+ | ||
+11.28% | 216B | B- | ||
+2.64% | 167B | C+ | ||
+6.72% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- JNJ Stock
- Ratings Johnson & Johnson